You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Master Class: Proteasome Inhibitor-Based Therapy

  • Authors: Rafat Abonour, MD; Thomas Martin, MD; Joseph Mikhael, MD, MEd, FRCPC
  • CME / ABIM MOC Released: 9/6/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/6/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with multiple myeloma.

The goal of this activity is to increase knowledge and competence for healthcare professionals managing care of patients undergoing treatment with proteasome inhibitor (PI)-based combination therapy for the treatment of multiple myeloma (MM).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding
    • Differentiating PI-based combination treatments for MM
  • Demonstrate greater confidence in their ability to
    • Select optimal PI-based regimens for appropriate patients with MM


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Joseph Mikhael, MD, MEd, FRCPC

    Chief Medical Officer
    International Myeloma Foundation
    Professor
    City of Hope Cancer Center
    Los Angeles, California

    Disclosures

    Disclosure: Joseph Mikhael, MD, MEd, FRCPC, FACP, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: AbbVie Inc.; Celgene Corporation; Sanofi

    Dr Mikhael does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Mikhael does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Rafat Abonour, MD

    Professor of Pathology & Laboratory Medicine
    Medical Director, Bone Marrow Transplant Program
    Medical Director, Stem Cell Laboratory
    Indiana University School of Medicine
    Indianapolis, Indiana

    Disclosures

    Disclosure: Rafat Abonour, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
    Received grants for clinical research from: Celgene Corporation; Takeda Pharmaceuticals North America, Inc.

    Dr Abonour does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Abonour does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Thomas Martin, MD

    Professor of Clinical Medicine
    UCSF Medical Center
    San Francisco, California

    Disclosures

    Disclosure: Thomas Martin, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Roche
    Received grants for clinical research from: Amgen Inc.; Sanofi

    Dr Martin does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Martin does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Sara Fagerlie, PhD, CHCP

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Master Class: Proteasome Inhibitor-Based Therapy

Authors: Rafat Abonour, MD; Thomas Martin, MD; Joseph Mikhael, MD, MEd, FRCPCFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 9/6/2018

Valid for credit through: 9/6/2019

processing....

Contents of This CME Activity

The Role of Proteasome Inhibition in Multiple Myeloma

Dr Mikhael gives an overview of how proteasome inhibitors function and are incorporated into the treatment paradigm for MM.
Joseph Mikhael, MD, MEd, FRCPC, FACP

Newly Diagnosed Multiple Myeloma

Dr Abonour discusses the current treatment approach for patients with newly diagnosed MM.
Rafat Abonour, MD

Relapsed/Refractory Multiple Myeloma

Dr Martin discusses the current treatment approach for patients with relapsed or refractory disease
Thomas Martin, MD